Metabolic monitoring for atypical antipsychotics (H.Elliott)
Metabolic monitoring for atypical antipsychotics Note: more comprehensive or frequent monitoring may be needed if chronic medical conditions exist [select name="Q1" value="Baseline|6 weeks after starting drug treatment|12 weeks after starting drug treatment|Annual"] <-- Interval [conditional field="Q1" condition="(Q1).is('Baseline')||(Q1).is('Annual')"]Medical history Blood pressure Body mass index Waist circumference Fasting glucose level Fasting lipid levels Lifestyle counseling[/conditional][conditional field="Q1" condition="(Q1).is('6 weeks after starting drug treatment')||(Q1).is('12 weeks after starting drug treatment')"]Blood pressure Body mass index Fasting glucose level Fasting lipid levels Lifestyle counseling[/conditional] [checkbox memo="display/hide references" name="footnotes" value=""][conditional field="footnotes" condition="(footnotes).is('')"] reference: [link url="//www.ncbi.nlm.nih.gov/pubmed/21804146" memo="#1"] De Hert M, Vancampfort D, Correll CU, Mercken V, Peuskens J, Sweers K, van Winkel R, Mitchell AJ. Guidelines for screening and monitoring of cardiometabolic risk in schizophrenia: systematic evaluation. Br J Psychiatry. 2011 Aug;199(2):99-105. [link url="http://www.nimh.nih.gov/health/publications/mental-health-medications/index.shtml#pub4" memo="#2"] NIMH - Antipsychotic medications [/conditional]
Result - Copy and paste this output:
Sandbox Metrics: Structured Data Index 1, 7 form elements, 22 boilerplate words, 1 checkboxes, 1 drop downs, 2 links, 3 conditionals, 2 total clicks
Send Feedback for this SOAPnote